The drug is crucial for patients suffering from bleeding disorders. Under the state guarantees program for medical care, the “Eitoplasm” treatment will be accessible to everyone at no cost. Although Federal Antimonopoly Service of Russia did not reveal the price of the medication, it remains a crucial aspect to consider.
According to the press center of FAS, this initiative will lead to intensified competition in the product market, ultimately causing a noteworthy decrease of costs in Russia’s drug market. By greatly slashing the prices of licensed medications compared to their international counterparts, they anticipate an impressive reduction of more than 8%. This measure will have a significant impact, significantly increasing the accessibility of vital treatments for the citizens of Russia.
